Valuation: Nutriband Inc.

Market Cap 35.01M 30.38M 28.45M 26.03M 49.05M 3.33B 49.8M 333M 131M 1.67B 131M 129M 5.55B P/E 2025
-8.39x
P/E 2026 -1.86x
Enterprise Value 30.68M 26.63M 24.93M 22.81M 42.99M 2.92B 43.64M 292M 114M 1.46B 115M 113M 4.86B EV / Sales 2025
41.1x
EV / Sales 2026 26.5x
Free-Float
43.12%
Yield 2025 *
-
Yield 2026 -
1 day+1.22%
1 week+1.22%
Current month+2.28%
1 month-4.74%
3 months-28.55%
6 months-32.91%
Current year-35.79%
1 week 2.8
Extreme 2.8
2.97
1 month 2.8
Extreme 2.8
3.29
Current year 2.8
Extreme 2.8
4.98
1 year 2.8
Extreme 2.8
8.63
3 years 1.53
Extreme 1.53
11.78
5 years 1.53
Extreme 1.53
12.86
10 years 0.86
Extreme 0.857142
43.54
Manager TitleAgeSince
Chief Executive Officer 35 01/01/2016
Chief Executive Officer 52 -
Director of Finance/CFO 77 02/09/2020
Director TitleAgeSince
Chairman 52 21/01/2022
Director/Board Member 48 01/07/2018
Director/Board Member 38 01/07/2018
Date Insider Type Main position Quantity % Market Cap.
31/01/25 Other

Founder

126,833 1.1420%
31/01/25 Option

Chief Financial Officer

212,837 1.9164%
20/03/24 Free

Chief Financial Officer

162,500 2.0745%
Change 5-day change 1-year change 3-year change Capi.($)
+1.22%+1.22%-57.88%-24.68% 35.01M
+2.13%-0.04%-17.39%+0.29% 183B
-0.08%-1.85%-4.18%+2.24% 110B
+2.46%+2.01%+11.17%+75.37% 61.72B
-1.64%+7.20%+39.25%+56.58% 54.98B
+3.76%+5.15%+0.10%-34.61% 47.02B
-5.88%-13.90% - - 32.16B
+0.44%+10.49%+10.02%-31.01% 31.19B
-0.69%+3.30%+45.94%-7.06% 24.7B
-0.40%-1.30%+3.53%+2.55% 22.68B
Average -0.16%+1.26%+3.40%+4.41% 56.75B
Weighted average by Cap. -0.21%+0.19%+1.37%+9.99%

Financials

2025 2026
Net sales 2.14M 1.86M 1.74M 1.59M 3M 204M 3.04M 20.34M 7.98M 102M 8.03M 7.86M 339M 2.04M 1.77M 1.65M 1.51M 2.85M 194M 2.9M 19.36M 7.6M 97M 7.65M 7.48M 323M
Net income -10.48M -9.1M -8.52M -7.79M -14.69M -997M -14.91M -99.66M -39.11M -499M -39.35M -38.5M -1.66B -8.23M -7.14M -6.69M -6.12M -11.53M -783M -11.71M -78.24M -30.7M -392M -30.9M -30.23M -1.3B
Net Debt -4.13M -3.58M -3.35M -3.07M -5.78M -392M -5.87M -39.22M -15.39M -196M -15.49M -15.15M -654M -4.33M -3.76M -3.52M -3.22M -6.07M -412M -6.16M -41.16M -16.15M -206M -16.25M -15.9M -686M
Logo Nutriband Inc.
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Employees
-
Date Price Change Volume
06/08/26 $2.915 +1.22% 2,990
05/08/26 $2.880 +1.05% 14,077
04/08/26 $2.850 +1.42% 6,993
03/08/26 $2.810 -1.40% 5,602
31/07/26 $2.850 -2.06% 8,872
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.915USD
Average target price
15.00USD
Spread / Average Target
+414.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTRB Stock